Eli Lilly and Company

About: Eli Lilly and Company is a company organization based out in Indianapolis, Indiana, United States. It is known for research contribution in the topics: Population & Receptor. The organization has 17826 authors who have published 22835 publications receiving 946714 citations. The organization is also known as: Eli Lily.

Apparatus and method for implantation of sensors

Abstract: An apparatus for implantation of in vivo sensors includes a housing, a dual-lumen tube extending therefrom, and an in vivo sensor received within one of the lumen of the tube. A needle is received within the other lumens of the tube, and is used to insert the tube through the skin. After implantation, the needle is removed, and the flexible tube and sensor remaining beneath the skin provides the user with reduced irritation and greater comfort. The associated method for subcutaneous implantation of a sensor for use in vivo is also disclosed.

Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene

Abstract: 17β-Estradiol modulates gene transcription through the estrogen receptor and the estrogen response element in DNA. The human transforming growth factor-β3 gene was shown to be activated by the estrogen receptor in the presence of estrogen metabolites or estrogen antagonists. Activation was mediated by a polypurine sequence, termed the raloxifene response element, and did not require the DNA binding domain of the estrogen receptor. Interaction of the estrogen receptor with the raloxifene response element appears to require a cellular adapter protein. The observation that individual estrogens modulate multiple DNA response elements may explain the tissue-selective estrogen agonist or antagonist activity of compounds such as raloxifene.

A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission

Abstract: The principal excitatory neurotransmitter in the vertebrate central nervous system, L-glutamate, acts on three classes of ionotripic glutamate receptors, named after the agonists AMPA (α-amino-3-hydroxy-5-methyl-4-isoxalole-4-propionic acid), NMDA ( N -methyl-D-aspartate) and kainate1 The development of selective pharmacological agents has led to a detailed understanding ofthe physiological and pathological roles of AMPA and NMDA receptors2,3,4,5,6,7,8 In contrast, the lack of selective kainate receptor ligands has greatly hindered progress in understanding the rolesof kainate receptors9,10 Here we describe the effects of a potent and selective agonist, ATPA (( RS)-2-amino-3-(3-hydroxy-5- tert -butylisoxazol-4-yl)propanoic acid) and a selective antagonist, LY294486 ((3SR, 4aRS, 6SR, 8aRS)-6-((((1H-tetrazol-5-yl) methyl)oxy)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic acid), of the GluR5 subtype of kainate receptor11 We have used these agents to show that kainate receptors, comprised of or containing GluR5 subunits, regulate synaptic inhibition in the hippocampus, an action that could contribute to the epileptogenic effects of kainate12,13,14,15,16,17